PacificGMP to Assist Novavax on Bird Flu Vaccine Production
Posted on: Wednesday, 1 March 2006, 12:01 CST
Novavax and PacificGMP have formed a strategic alliance to collaborate on the development of a commercial scale production process for Novavax's experimental pandemic bird flu vaccine and other biological products.
Under the alliance, PacificGMP will assist Novavax in developing the capability of manufacturing large quantities of vaccine to accommodate the surge capacity that must be met in the event of a pandemic outbreak of influenza.
PacificGMP will utilize disposable bioprocessing technology to manufacture and produce Novavax's VLP avian flu vaccine. Use of this disposable bioprocessing technology will allow for faster production, with greatly reduced overall manufacturing costs.
This process also mitigates the possibility for cross-contamination in production which should ultimately result in a VLP avian flu vaccine that will be available to the public in a much shorter time period.
"This agreement with PacificGMP brings another critical capability to Novavax in the development of our H5N1 avian influenza VLP vaccine, and puts Novavax a step closer to servicing the world at large in the event of a pandemic." said Dr Rahul Singhvi, president and CEO of Novavax.
Source: Datamonitor
Related Articles
- Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico
- Novavax Vaccine Provides Immune Response
- Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
- Novavax and Collaborators Significantly Improve VLP Vaccine for HIV/AIDS
- Netherlands Begins Vaccination of Chickens Against Bird Flu
- New Vaccines Necessary for New Bird Flu Strain: U.S. Official
- 43 Tons of Chinese Vaccines Help Vietnam Combat Bird Flu
- Short-Order DNA Vaccine May Offer Protection Against a Flu Pandemic
- Biosecurity, Vaccine Screenings Prioritized Against Bird Flu in Indonesia
- Avian Flu Vaccine Set for U.S. Production
 |
 |
User Comments (0)
RSS Feeds